Stocks · Healthcare · Biotechnology
AN2 Therapeutics, Inc. ANTX
$5.71 +1.60% Close, Oct 2, 2026 · NASDAQ · Market cap $205.7M
Strong trend
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The diluted share count rose 48.4% in a year.
- Over the past year the stock returned +342.6%, ahead of the S&P 500 by 327.6 percentage points.
- The stock is in an uptrend: above its 200-day average for 148 trading days, with the 50-day average above the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 24%
- Accruals (lower is better)Top 49%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 34%
- Free-cash-flow yieldBottom 30%
- EBITDA / enterprise valueBottom 26%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 2%
- 6-month returnTop 13%
- 1-year return vs S&P 500Top 3%
- Distance from 52-week highTop 33%
- Trend checklist (0–4)Top 7%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 25%
- Consecutive EPS beatsBottom 49%
- Share of analysts rating BuyBottom 28%
- Upside to consensus price targetBottom 48%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 46%
- Maximum drawdown, 3 yearsBottom 4%
- Beta vs S&P 500 (lower is better)Top 1%
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Return on invested capital | -51.0% | — | Bottom 24% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -6.8%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -19.03%
- Shareholder yield
- -19.03%
- Share count change, 1 year
- +48.4%
- Share count change, 3-year CAGR
- +31.9%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 11, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 1
- Beats in the last 8 reports
- 2 of 8
- Average EPS surprise, last 4
- -14.2%
- Average 2-day reaction, last 8
- +0.5%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $9.00
- Target vs current price
- +57.6%
- Analysts with a rating
- 8
- Share rating Buy or Strong Buy
- 63%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 11, 2026 | +25.0% | -0.7% | -3.0% | +1.2% | — |
| May 11, 2026 | -26.1% | +5.8% | +6.5% | -13.7% | +30.9% |
| Mar 17, 2026 | -20.8% | +6.6% | -18.3% | -36.5% | -10.4% |
| Nov 12, 2025 | -34.8% | -1.7% | -6.7% | -1.7% | -10.0% |
| Aug 12, 2025 | +32.3% | +0.0% | +6.7% | +10.5% | +8.6% |
| May 13, 2025 | -34.6% | -0.8% | +0.0% | -6.7% | -9.2% |
| Mar 25, 2025 | +0.0% | -0.7% | -9.9% | -12.6% | -27.2% |
| Nov 13, 2024 | -16.2% | -4.7% | +0.0% | +46.2% | +4.7% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 11, 2026 | -$0.18 | -$0.24 | +25.0% | — |
| May 11, 2026 | -$0.29 | -$0.23 | -26.1% | — |
| Mar 17, 2026 | -$0.29 | -$0.24 | -20.8% | — |
| Nov 12, 2025 | -$0.31 | -$0.23 | -34.8% | — |
| Aug 12, 2025 | -$0.21 | -$0.31 | +32.3% | — |
| May 13, 2025 | -$0.35 | -$0.26 | -34.6% | — |
| Mar 25, 2025 | -$0.25 | -$0.25 | +0.0% | — |
| Nov 13, 2024 | -$0.43 | -$0.37 | -16.2% | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| Free-cash-flow yield | -14.92% | — | — | Bottom 30% |
| Earnings yield | -18.74% | — | — | Bottom 34% |
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 2
- Days above the 200-day average
- 148
- 50-day average slope (20 days)
- +4.3%
- 200-day average slope (20 days)
- +12.5%
- Distance from 50-day average
- +3.5%
- Distance from 200-day average
- +51.2%
- RSI (14)
- 60.6
- Relative volume
- 1.83×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 53.5%
- Volatility vs own 5-year history
- 17th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- -0.28
- Correlation with S&P 500
- -0.03
- Current drawdown from 1-year high
- -9.1%
- Maximum drawdown, 3 years
- -95.4%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Aug 15, 2022 | Aug 16, 2024 | -95.6% | 504 days | Not yet recovered |
| May 6, 2022 | Aug 1, 2022 | -59.6% | 58 days | 9 days (Aug 12, 2022) |
| Apr 4, 2022 | Apr 11, 2022 | -13.5% | 5 days | 12 days (Apr 28, 2022) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $205.7M
- EPS, diluted (TTM)
- -$1.07
- Revenue (TTM)
- $0
- 52-week range
- $1.00 – $7.19
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | -$77,000 | $0 | $0 | $0 |
| Operating income | -$21.6M | -$42.3M | -$69.6M | -$54.6M | -$38.1M |
| Net income | -$21.5M | -$41.0M | -$64.7M | -$51.3M | -$35.2M |
| EPS (diluted) | -$1.50 | -$2.79 | -$2.74 | -$1.72 | -$1.16 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$12.7M | -$7.5M | -$10.6M | -$6.5M | -$9.4M | -$8.7M | -$10.0M | -$8.2M |
| EPS (diluted) | -$0.43 | -$0.25 | -$0.35 | -$0.21 | -$0.31 | -$0.29 | -$0.29 | -$0.18 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$20.5M | -$33.5M | -$53.3M | -$49.3M | -$29.8M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 |
| Free cash flow | -$20.5M | -$33.5M | -$53.3M | -$49.3M | -$29.8M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $0 | $70.4M | $84.5M | $372,000 | $113,000 |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $78.4M
- Total assets
- $81.7M
- Total liabilities
- $5.8M
- Total debt
- $0
- Net debt
- -$44.3M
- Shareholders’ equity
- $75.9M
As of Jun 30, 2026 (filed Aug 11, 2026).
Dividends
| Ex-date | Amount | Paid |
|---|---|---|
| Jan 11, 2018 | $0.66 | — |
| Oct 12, 2017 | $0.66 | — |
| Jul 12, 2017 | $0.66 | — |
| Apr 11, 2017 | $0.66 | — |
| Jan 11, 2017 | $0.66 | — |
| Oct 12, 2016 | $0.66 | — |
| Jul 13, 2016 | $0.66 | — |
| Apr 13, 2016 | $0.66 | — |
Short interest
- Shares sold short
- 2,397,307
- Days to cover
- 11.79
- Change vs previous report
- -4.4%
FINRA short interest, settlement date Sep 15, 2026.